TAG1 and NRG Pallas have signed a letter of intent to jointly expand access to lead-212 for cancer therapy development across Europe.
The agreement builds on an existing supply arrangement under which NRG Pallas will continue to deliver high-purity radium-224 to TAG1 through 2028, according to the companies.
The collaboration will combine TAG1’s proprietary portable lead-212 generator with NRG Pallas’ radium-224 production capabilities. The companies said the goal is to address supply challenges facing the radiopharmaceutical industry.
Together, the firms plan to deliver preclinical and clinical quantities of the isotope to cancer drug developers across Europe. Target users include therapeutic companies and hospital-based adult and pediatric oncology programs.
The partnership is also exploring how the work could support Lead4Life, a Dutch public-private program focused on lead-212-based radiopharmaceuticals. NRG Pallas said the initiative includes production and supply-chain development.
Lead4Life received a €5M public-private partnership grant from Health~Holland and is set to launch in 2026, according to NRG Pallas. The program includes work on pharmaceutical-grade lead-212 availability and supporting technologies such as dosimetry, imaging, radiation protection, waste management, and radiobiological substantiation.
Company:Tag1
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
